Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Other financing activities (2016 - 2022)

Bio-Techne (TECH) has 14 years of Other financing activities data on record, last reported at -$2.5 million in Q3 2022.

  • For Q3 2022, Other financing activities fell 113.43% year-over-year to -$2.5 million; the TTM value through Jun 2023 reached -$2.5 million, down 411.8%, while the annual FY2023 figure was -$2.5 million, 411.8% down from the prior year.
  • Other financing activities reached -$2.5 million in Q3 2022 per TECH's latest filing, up from -$23.6 million in the prior quarter.
  • Across five years, Other financing activities topped out at $27.1 million in Q1 2021 and bottomed at -$23.6 million in Q1 2022.
  • Average Other financing activities over 5 years is $2.9 million, with a median of $3.1 million recorded in 2018.
  • Peak YoY movement for Other financing activities: tumbled 2149.48% in 2018, then surged 1704.73% in 2021.
  • A 5-year view of Other financing activities shows it stood at -$7.7 million in 2018, then soared by 147.83% to $3.7 million in 2019, then rose by 29.73% to $4.8 million in 2020, then increased by 27.08% to $6.1 million in 2021, then tumbled by 140.28% to -$2.5 million in 2022.
  • Per Business Quant database, its latest 3 readings for Other financing activities were -$2.5 million in Q3 2022, -$23.6 million in Q1 2022, and $6.1 million in Q4 2021.